

What is wrong with EVAR and how would a perfect device overcome the problems?

Bijan Modarai

Professor of Vascular Surgery

Academic Department of Vascular Surgery

Guy's & St Thomas' NHS Foundation Trust, King's College London

INTERNATIONAL EXPERTS SYMPOSIUM
CRITICAL ISSUES
in aortic endografting

 KING'S
HEALTH
PARTNERS

NHS

Guy's and St Thomas'
NHS Foundation Trust

Disclosures


Cook:

Proctoring, Speaker's fees, Grant support, Consulting


Cydar Medical:

Scientific advisory board


DREAM



Medicare Data



EVAR 1



Schermerhorn et al. N Eng J Med 2015

Van Schaik et al. J Vasc Surg 2017


Patel et al. Lancet 2016

DREAM




Medicare Data

~50% survival at 10 years





EVAR 1



Schermerhorn et al. *N Eng J Med* 2015

Van Schaik et al. *J Vasc Surg* 2017

Patel et al. *Lancet* 2016



Van Schaik et al. J Vasc Surg 2017

Patel et al. Lancet 2016




Reintervention



A population-based cohort study examining the risk of abdominal cancer after endovascular abdominal aortic aneurysm repair


Sheraz R. Markar, PhD, MA, MSc, MRCS,^a Alberto Vidal-Diez, PhD,^{b,c} Viknesh Sounderajah, MRCS,^a Hugh Mackenzie, PhD, MRCS,^a George B. Hanna, PhD, FRCS,^a Matt Thompson, PhD, FRCS,^b Peter Holt, PhD, FRCS,^b Jesper Lagergren, PhD, MD,^{d,e} and Alan Karthikesalingam, PhD, MA, MSc, MRCS,^{a,b,c}
London, United Kingdom; and Stockholm, Sweden

Abdominal cancer



HR 1.14 (CI 1.03-1.27, P=0.02)


All cancers



HR 1.09 (CI 1.02-1.16, P=0.02)

A population-based cohort study examining the risk of abdominal cancer after endovascular abdominal aortic aneurysm repair



Sheraz R. Markar, PhD, MA, MSc, MRCS,^a Alberto Vidal-Diez, PhD,^{b,c} Viknesh Sounderajah, MRCS,^a Hugh Mackenzie, PhD, MRCS,^a George B. Hanna, PhD, FRCS,^a Matt Thompson, PhD, FRCS,^b Peter Holt, PhD, FRCS,^b Jesper Lagergren, PhD, MD,^{d,e} and Alan Karthikesalingam, PhD, MA, MSc, MRCS,^{a,b,c} London, United Kingdom; and Stockholm, Sweden




NHS 1.14 (CI 1.03-1.27, P=0.02)

HR 1.09 (CI 1.02-1.16, P=0.01)

Stent graft evolution



Stent graft evolution



Stent graft evolution

Materials

Fixation

Profile

Deployment



EVAR Challenges

Device integrity

Disease progression

Device fixation

Case selection


Endoleak

Radiation exposure

Limb occlusion


Surveillance

Active fixation reduces migration




Force to dislodge stent graft 6X less than sutured anastomosis.

Resch et al. EJVES 2000



- **Cadaveric model**
- **Fixation hooks/barbs: Higher DF**
- **Less migration**

Melas et al. EJVES 2010



Systematic review and meta-analysis of migration after endovascular abdominal aortic aneurysm repair

Vascular
2016, Vol. 24(3) 323–336
© The Author(s) 2015
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/1708538115590065
vas.sagepub.com


Talent, Excluder, Aneurx, Zenith

Factors associated with migration:

Aneurysm diameter

Neck length

Neck length

4mm



1cm





1.5cm




**Current endograft technology
relies almost exclusively on
mechanical interaction between
device and native vessels to
afford stability**

Tissue-engineered stent-graft integrates with aortic wall by recruiting host tissue into graft scaffold



J Thorac Cardiovasc Surg 2014;148:1719-25

Development of a prostacyclin-agonist–eluting aortic stent graft enhancing biological attachment to the aortic wall




- **Canine model**
- **Enhanced neointimal formation and fibrous tissue**
- **Strengthening the mechanical force of attachment graft/aorta.**



- Maintenance of aortic integrity at seal zones.....
- Risk factors: thrombus, ectasia, synchronous aneurysms
- Occult underlying genetic factors?
- Oversizing promotes degeneration

Stent grafts that “fail well”

Aneurysmal disease





Elastase inhibitor AZD9668 treatment prevented progression of experimental abdominal aortic aneurysms

Sandrine Delbosc, PhD,^{a,b} Martin Rouer, MD,^a Jean-Marc Alsac, MD, PhD,^{a,c} Liliane Louedec, MsSC,^{a,b} Monique Philippe, MsSC,^{a,b} Olivier Meilhac, PhD,^{a,b} Carl Whatling, PhD,^d and Jean-Baptiste Michel, MD, PhD,^{a,b} *Paris, France; and Molndal, Sweden*


- **Leucocyte produces elastase**
- **Elastase murine model**
- **AZD9668 (AtraZeneca elastase inhibitor)**
- **Inhibits aneurysm progression**

Prior to relining



After relining



Aneurysm sac management





- **Endoleak at 30 days:**
 - Heralds re-intervention**
- **Malignant type 2 endoleaks**
- **Endoleaks masquerading as type 2**
- **Relevance of sac content?**
- **Advanced imaging of sac/aortic wall**
- **Devices that obliterate sac**



Device profile and hostile iliac anatomy

- **Ideal system:**
 - Low profile
 - Well supported limbs
 - Flexible/compliant
 - Vessel stenosis: Radial force
 - Flexible/hydrophilic delivery system
 - Percutaneous
- **Low profile: Compromise on materials?**



Carefully executed EVAR with conservative IFU performs well

How hard should we strive to increase applicability of devices?

Adverse anatomy → Complications

The future: Imaging, AI and machine learning



- **Objective case selection**
 - Accounting for multiple nuances
 - Deformation
 - Available neck length
 - Stent graft conformation
 - Precise deployment
- **Stent graft longevity**
- **Patient longevity**
- **Tailored surveillance**

CAUTION



X-RAY RADIATION



BSCSafetySigns.com.au W61

NHS

Guy's and St Thomas'
NHS Foundation Trust


 KING'S
HEALTH
PARTNERS

Fiber Optic RealShape (FORS) technology



- Real time 3D device visualisation using light
- Multiple unrestricted viewing angles
- Corresponding alignment markers on stent graft?

Fault Detection System for a Stent-Graft Endoleakage Monitor



Endovascular Aneurysm Repair (EVAR) Market is growing with \$3,580 Million Value Globally by 2023

 MARCH 22ND, 2019

 ALLIED MARKET RESEARCH

 RELEASES

 Facebook

 Twitter

 LinkedIn

- **Iterative improvements from lessons of past**
- **Paradigm shifts still possible? - Yes**
- **Novel technology: Increasing regulatory scrutiny**

Towards Perfection

Flexibility, strength, support, durable, low profile, precise delivery

Actively prevents disease progression

Incorporates into seals zones

Obliterates aneurysm sac

Facilitates proximal/distal extension

Radiation free implantation/surveillance

Actively warns of malfunction

Perfection

Flexibility, strength, support, durable, low profile, precise delivery

Actively prevents disease progression

Incorporates into seals zones

Obliterates aneurysm sac

Facilitates proximal/distal extension

Radiation free implantation/surveillance

Actively warns of malfunction

Radiation

MRI compatible graft materials - no artefact

FORS and markers on graft that allow you to see exactly where
You are – wire in renal and markers on graft – then you deploy

